Hepatic Encephalopathy

Lusutrombopag Under Priority Review for Thrombocytopenia in Liver Disease

By February 26, 2018

The primary endpoint was the number of patients who required no platelet transfusion priory to primary invasive procedure and no rescue therapy for bleeding for 7 days post-procedure.

APAP, Non-APAP Induced Acute Liver Failure More Likely in Women

By November 11, 2016

Gender differences have been established for most chronic liver diseases but less is known with acute liver failure.

Mortality Rates in Cirrhosis, UGIB Cut With Timely Antibiotic Administration

October 31, 2016

Timely administration of antibiotics is associated with a reduction in mortality among patients with cirrhosis and upper gastrointestinal bleeding (UGIB), according to a study published in the November issue of Clinical Gastroenterology and Hepatology.

Low Risk of Hepatic Decompensation With PrOD Regimen, Study Finds

By October 30, 2016

The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.

Is There a Benefit to Adding Rifaximin to Lactulose in Acute Hepatic Encephalopathy?

By May 11, 2016

Adding rifaximin to lactulose treatment for acute hepatic encephalopathy did not shorten hospital length of stay but it did lower readmission rates at 180 days, study authors reported in a study published in the Journal of Pharmacy Practice.

Liver Injury from CAM Just as Bad as with Prescription Meds

By April 07, 2016

Complementary and alternative medicine (CAM)-induced drug-induced liver injury (DILI) is as severe in presentation as that seen with prescription medicine (PM)-induced DILI with higher rates of transplantation and lower transplant-free survival in patients who progress to acute liver failure, a new report in The American Journal of Gastroenterology has shown.

Drug Used for Organ Rejection Prophylaxis Effective in Autoimmune Hepatitis

By March 22, 2016

Mycophenolate mofetil appears safe and effective for the treatment of autoimmune hepatitis (AIH), according to the results of a study published in Alimentary Pharmacology & Therapeutics.

Hep E Transmission Occurs After Plasma Exchange

March 02, 2016

A case of hepatitis E virus (HEV) infection has been reported in a kidney transplant recipient, according to a research letter published online March 1 in the Annals of Internal Medicine.

Nutritional Therapy Ups Liver Function in Minimal Hepatic Encephalopathy

By November 16, 2015

In patients with minimal hepatic encephalopathy, nutritional therapy is effective and improves HRQOL, a randomized controlled trial presented during The Liver Meeting® 2015 has reported.

Lactulose Improves QoL in Patients with Minimal Hepatic Encephalopathy

By November 16, 2015

In patients with minimal hepatic encephalopathy, prophylactic lactulose treatment improves cognition, quality of life, and intestinal microbiota, results of a multicenter, randomized, controlled trial presented at The Liver Meeting® 2015 have shown.

Adding Everolimus Early Linked to Less Weight Gain Post-Transplant

By November 15, 2015

Adding everolimus (EVR) to reduced-tacrolimus (TAC) or eliminating TAC is associated with reduced long-term weight gain among patients who undergo liver transplantation, according to a study reported at the The Liver Meeting® 2015.

Modest Survival Benefit With Sorafenib in Advanced HCC Patients

By November 15, 2015

Sorafenib was associated with a modest survival benefit in patients with advanced hepatocellular carcinoma (HCC), particiularly in patients with decompensation, data presented at The Liver Meeting® 2015 presented.

Longer Survival for HBV-Related Hepatocellular Carcinoma with Entecavir

By November 14, 2015

Entecavir is associated with longer survival times than lamivudine among patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC), according to a study reported at the The Liver Meeting® 2015.

PPIs Reduce Rebleeding in Patients with Cirrhosis, Acute Variceal Bleeding

By November 14, 2015

Proton pump inhibitors (PPIs) are safe and effective in reducing the rate of recurrent bleeding among patients with cirrhosis and acute variceal bleeding, according to a single-institution case-control study reported at the The Liver Meeting® 2015.

Carvedilol Improves Portal Pressure in Patients with Advanced Cirrhosis

By November 14, 2015

Response rates among patients with advanced liver cirrhosis who were administered carvedilol to reduce portal pressure were superior to those achieved with propranolol, according to authors of the randomized, open-label, long-term CARPE study. Findings were reported at The Liver Meeting® 2015.

Daclatasvir/Sofosbuvir Improves Liver Parameters in HCV, Advanced Cirrhosis

By November 14, 2015

Patients from the advanced cirrhosis cohort of the Phase 3 ALLY-1 study had high rates of sustained virologic response (SVR12) when treated with daclatasvir/sofosbuvir/ribavirin, as well as improved clinical and biochemical indicators of liver disease, investigators reported at The Liver Meeting® 2015.

Poor HCC Recurrence-Free Survival Despite Prevention With Nucleos(t)ide Analog Tx

By November 14, 2015

Cirrhotic patients who develop hepatocellular carcinoma (HCC) despite secondary prevention therapy with nucleos(t)ide analog (NUC) treatment appear to have poor recurrence-free survival (RFS) after surgery than those who do not undergo secondary prevention, reported authors of a new study presented at The Liver Meeting® 2015.

Which HCV Regimens Report Higher Adherence Levels?

By November 14, 2015

Non-adherence to antiviral regimens may be predicted by the use of pegylated interferon, ribavirin, duration of treatment, and lower baseline and on-treatment patient-reported outcomes (PRO) scores, reported Zobair Younossi, MD, MPH, from Inova Fairfax Hospital, Falls Church, VA, at The Liver Meeting® 2015.

Aspirin Use May Lower Cholangiocarcinoma Risk Up to 3-Fold

By November 14, 2015

Use of aspirin significantly reduced the risk of three subtypes of cholangiocarcinoma, data presented at The Liver Meeting® 2015 have shown.

Are Beta-Blockers Safe in Cirrhotic Patients With Refractory Ascites?

By November 14, 2015

Treatment with non-selective beta-blockers in cirrhotic patients with refractory ascites may further deteriorate cardiac function, researchers reported at The Liver Meeting® 2015.

Low-Dose Rifaximin Cuts Endotoxin Level in Cirrhosis

October 29, 2015

Similar reduction in serum endotoxin level for low-dose, high-dose rifaximin

Body Building Supplement May Cause Serious Liver Injury

By April 14, 2015

The FDA is warning consumers to stop using Tri-Methyl Xtreme, a dietary supplement marketed to contain anabolic steroids for muscle growth.

Positive Response with Repeat Rifaximin Treatment in IBS-D

July 01, 2014

Salix announced results from the Phase 3 TARGET 3 trial evaluating the use of repeat treatment with rifaximin 550mg in patients with irritable bowel syndrome with diarrhea (IBS-D).

OxyElite Pro Supplements Recalled Due to Liver Illness

November 11, 2013

USPlabs LLC is recalling certain OxyElite Pro dietary supplement products after a letter from the FDA stated that the products have been linked to liver illnesses and that there is reasonable probability that the products are adulterated.

Risk Down for Deceased-Donor Partial Liver Transplant

June 12, 2013

For young pediatric patients, the risk associated with deceased-donor partial liver transplantation has decreased over time.

FibroScan Approved for Non-invasive Liver Diagnosis

April 16, 2013

Echosens' FibroScan device, used in the clinical management of patients with liver disease such as chronic viral hepatitis C and B and fatty liver diseases, has received clearance from the FDA.

N-acetylcysteine Use Improves Liver Graft Survival

March 04, 2013

Liver graft survival, postoperative complications, and the prevalence of primary liver dysfunction in suboptimal grafts are all significantly improved by the infusion of N-acetylcysteine (NAC) during liver procurement.

Increase in Proportion of Livers Not Used for Transplantation

January 22, 2013

The proportion of livers not used for transplantation is increasing, with the primary causes being donation after cardiac death (DCD), older donor age, greater body mass index (BMI), and increasing diabetes prevalence.

Orphan Drug Designation Granted for Terlipressin Formulation for Ascites

January 04, 2013

PharmaIN and LAT Pharma announced that the FDA has granted their request for orphan drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

QoL Up for Live Liver Donors Versus General Population

November 06, 2012

Living liver donors from Japan have higher health-related quality of life (HRQOL) than the Japanese norm population.